BTK and B-cell chronic lymphocytic leukemia: DTRMWXHS-12 (DTRM-12) (NCT02900716) is a pyrazolo-pyrimidine derivative irreversible BTK inhibitor currently under phase 1 and phase 2 clinical trials for CLL and NHL [82].